Loading…

Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97

In November 1996, 11 lots of one U.S. manufacturer’s 1996–97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccinat...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2000-01, Vol.18 (11), p.1103-1109
Main Authors: Buxton Bridges, C, Fukuda, K, Holman, R.C, De Guzman, A.M, Hodder, R.A, Gomolin, I.H, Galligan, G.K, Leib, H.B, Gallo, R.J, Regnery, H.L, Arden, N.H, Cox, N.J
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-bf66a2cf9fb3c467363803fe00a86975cfdad5474339e3799961cf1012085ecd3
cites
container_end_page 1109
container_issue 11
container_start_page 1103
container_title Vaccine
container_volume 18
creator Buxton Bridges, C
Fukuda, K
Holman, R.C
De Guzman, A.M
Hodder, R.A
Gomolin, I.H
Galligan, G.K
Leib, H.B
Gallo, R.J
Regnery, H.L
Arden, N.H
Cox, N.J
description In November 1996, 11 lots of one U.S. manufacturer’s 1996–97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer’s vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996–97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer ≥1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 ( p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.
doi_str_mv 10.1016/S0264-410X(99)00372-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70791744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X99003722</els_id><sourcerecordid>17462653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-bf66a2cf9fb3c467363803fe00a86975cfdad5474339e3799961cf1012085ecd3</originalsourceid><addsrcrecordid>eNqFkU1rFTEUhoMo9rb6E5RZSFFwNB-TZLKS0voFBRcquAu5yYmNzCTXZOZKXbl033_oLzG3c6nuujpvOM97TjgvQo8IfkEwES8_Yiq6tiP4y1OlnmHMJG3pHbQivWQt5aS_i1Y3yAE6LOUbxpgzou6jA4K5wozRFfp9BjaDKeAaE6ewTu6yyVA2KRZozJji1ybOuYRaL9IIu15wEKfS_LhI9WUhbKu3CjMMVYTohxniT9NsjbUh1iFx1y7zUD3JV7k0zBRSfN4QpcSfX1dKPkD3vBkKPNzXI_T5zetPp-_a8w9v35-enLe2o2Rq114IQ61Xfs1sJyQTrMfMA8amF0py651xvJMdYwqYVHU8sb5ejOKeg3XsCB0vczc5fZ-hTHoMxcIwmAhpLlpiqYjsulvBCgkqOKsgX0CbUykZvN7kMJp8qQnWu6z0dVZ6F4RWSl9npWn1Pd4vmNcjuP9cSzgVeLIHTKnn9dlEG8o_jgrKFa_YqwWDerZtgKyLDRAtuFBjmbRL4Zaf_AX6ErLG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17462653</pqid></control><display><type>article</type><title>Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Buxton Bridges, C ; Fukuda, K ; Holman, R.C ; De Guzman, A.M ; Hodder, R.A ; Gomolin, I.H ; Galligan, G.K ; Leib, H.B ; Gallo, R.J ; Regnery, H.L ; Arden, N.H ; Cox, N.J</creator><creatorcontrib>Buxton Bridges, C ; Fukuda, K ; Holman, R.C ; De Guzman, A.M ; Hodder, R.A ; Gomolin, I.H ; Galligan, G.K ; Leib, H.B ; Gallo, R.J ; Regnery, H.L ; Arden, N.H ; Cox, N.J</creatorcontrib><description>In November 1996, 11 lots of one U.S. manufacturer’s 1996–97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer’s vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996–97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer ≥1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 ( p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(99)00372-2</identifier><identifier>PMID: 10590332</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Viral - blood ; Biological and medical sciences ; Elderly ; Epidemiology. Vaccinations ; Female ; General aspects ; Hemagglutination Inhibition Tests ; Humans ; Infectious diseases ; Influenza vaccine ; Influenza Vaccines - immunology ; Male ; Medical sciences ; Nursing home ; Nursing Homes ; Potency ; Time Factors ; Vaccination</subject><ispartof>Vaccine, 2000-01, Vol.18 (11), p.1103-1109</ispartof><rights>2000</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-bf66a2cf9fb3c467363803fe00a86975cfdad5474339e3799961cf1012085ecd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1262595$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10590332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buxton Bridges, C</creatorcontrib><creatorcontrib>Fukuda, K</creatorcontrib><creatorcontrib>Holman, R.C</creatorcontrib><creatorcontrib>De Guzman, A.M</creatorcontrib><creatorcontrib>Hodder, R.A</creatorcontrib><creatorcontrib>Gomolin, I.H</creatorcontrib><creatorcontrib>Galligan, G.K</creatorcontrib><creatorcontrib>Leib, H.B</creatorcontrib><creatorcontrib>Gallo, R.J</creatorcontrib><creatorcontrib>Regnery, H.L</creatorcontrib><creatorcontrib>Arden, N.H</creatorcontrib><creatorcontrib>Cox, N.J</creatorcontrib><title>Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In November 1996, 11 lots of one U.S. manufacturer’s 1996–97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer’s vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996–97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer ≥1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 ( p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Elderly</subject><subject>Epidemiology. Vaccinations</subject><subject>Female</subject><subject>General aspects</subject><subject>Hemagglutination Inhibition Tests</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Influenza vaccine</subject><subject>Influenza Vaccines - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nursing home</subject><subject>Nursing Homes</subject><subject>Potency</subject><subject>Time Factors</subject><subject>Vaccination</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkU1rFTEUhoMo9rb6E5RZSFFwNB-TZLKS0voFBRcquAu5yYmNzCTXZOZKXbl033_oLzG3c6nuujpvOM97TjgvQo8IfkEwES8_Yiq6tiP4y1OlnmHMJG3pHbQivWQt5aS_i1Y3yAE6LOUbxpgzou6jA4K5wozRFfp9BjaDKeAaE6ewTu6yyVA2KRZozJji1ybOuYRaL9IIu15wEKfS_LhI9WUhbKu3CjMMVYTohxniT9NsjbUh1iFx1y7zUD3JV7k0zBRSfN4QpcSfX1dKPkD3vBkKPNzXI_T5zetPp-_a8w9v35-enLe2o2Rq114IQ61Xfs1sJyQTrMfMA8amF0py651xvJMdYwqYVHU8sb5ejOKeg3XsCB0vczc5fZ-hTHoMxcIwmAhpLlpiqYjsulvBCgkqOKsgX0CbUykZvN7kMJp8qQnWu6z0dVZ6F4RWSl9npWn1Pd4vmNcjuP9cSzgVeLIHTKnn9dlEG8o_jgrKFa_YqwWDerZtgKyLDRAtuFBjmbRL4Zaf_AX6ErLG</recordid><startdate>20000106</startdate><enddate>20000106</enddate><creator>Buxton Bridges, C</creator><creator>Fukuda, K</creator><creator>Holman, R.C</creator><creator>De Guzman, A.M</creator><creator>Hodder, R.A</creator><creator>Gomolin, I.H</creator><creator>Galligan, G.K</creator><creator>Leib, H.B</creator><creator>Gallo, R.J</creator><creator>Regnery, H.L</creator><creator>Arden, N.H</creator><creator>Cox, N.J</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000106</creationdate><title>Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97</title><author>Buxton Bridges, C ; Fukuda, K ; Holman, R.C ; De Guzman, A.M ; Hodder, R.A ; Gomolin, I.H ; Galligan, G.K ; Leib, H.B ; Gallo, R.J ; Regnery, H.L ; Arden, N.H ; Cox, N.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-bf66a2cf9fb3c467363803fe00a86975cfdad5474339e3799961cf1012085ecd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Elderly</topic><topic>Epidemiology. Vaccinations</topic><topic>Female</topic><topic>General aspects</topic><topic>Hemagglutination Inhibition Tests</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Influenza vaccine</topic><topic>Influenza Vaccines - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nursing home</topic><topic>Nursing Homes</topic><topic>Potency</topic><topic>Time Factors</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buxton Bridges, C</creatorcontrib><creatorcontrib>Fukuda, K</creatorcontrib><creatorcontrib>Holman, R.C</creatorcontrib><creatorcontrib>De Guzman, A.M</creatorcontrib><creatorcontrib>Hodder, R.A</creatorcontrib><creatorcontrib>Gomolin, I.H</creatorcontrib><creatorcontrib>Galligan, G.K</creatorcontrib><creatorcontrib>Leib, H.B</creatorcontrib><creatorcontrib>Gallo, R.J</creatorcontrib><creatorcontrib>Regnery, H.L</creatorcontrib><creatorcontrib>Arden, N.H</creatorcontrib><creatorcontrib>Cox, N.J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buxton Bridges, C</au><au>Fukuda, K</au><au>Holman, R.C</au><au>De Guzman, A.M</au><au>Hodder, R.A</au><au>Gomolin, I.H</au><au>Galligan, G.K</au><au>Leib, H.B</au><au>Gallo, R.J</au><au>Regnery, H.L</au><au>Arden, N.H</au><au>Cox, N.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2000-01-06</date><risdate>2000</risdate><volume>18</volume><issue>11</issue><spage>1103</spage><epage>1109</epage><pages>1103-1109</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>In November 1996, 11 lots of one U.S. manufacturer’s 1996–97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer’s vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996–97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer ≥1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 ( p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10590332</pmid><doi>10.1016/S0264-410X(99)00372-2</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2000-01, Vol.18 (11), p.1103-1109
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_70791744
source ScienceDirect Freedom Collection 2022-2024
subjects Aged
Aged, 80 and over
Antibodies, Viral - blood
Biological and medical sciences
Elderly
Epidemiology. Vaccinations
Female
General aspects
Hemagglutination Inhibition Tests
Humans
Infectious diseases
Influenza vaccine
Influenza Vaccines - immunology
Male
Medical sciences
Nursing home
Nursing Homes
Potency
Time Factors
Vaccination
title Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996–97
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A44%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20antibody%20response%20among%20nursing%20home%20residents%20who%20received%20recalled%20influenza%20vaccine%20and%20results%20of%20revaccination,%201996%E2%80%9397&rft.jtitle=Vaccine&rft.au=Buxton%20Bridges,%20C&rft.date=2000-01-06&rft.volume=18&rft.issue=11&rft.spage=1103&rft.epage=1109&rft.pages=1103-1109&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(99)00372-2&rft_dat=%3Cproquest_cross%3E17462653%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-bf66a2cf9fb3c467363803fe00a86975cfdad5474339e3799961cf1012085ecd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17462653&rft_id=info:pmid/10590332&rfr_iscdi=true